MicroRNAs (miRs) are potential therapeutic targets in glioblastoma multiforme (GBM), but
the difficulties associated with their delivery to tumor target cells have hampered their …

Glioma is the most common primary intracranial malignancy in the central nervous system.
At present, the most important treatment option is surgical resection of the tumor combined …

Therapeutic effect of glioma is often limited due to low permeability of delivery systems
across the Blood-Brain Barrier (BBB) and poor penetration into the tumor tissue. In order to …

Malignant gliomas are characterized by a short median survival which is largely impacted by
the resistance of these tumors tochemo‐and radiotherapy. Recent studies suggest that a …

MicroRNAs (miRNAs) have emerged as potential cancer therapeutics; however, their clinical
use is hindered by lack of effective delivery mechanisms to tumor sites. Mesenchymal stem …

Glioblastomas (GBM), the most common and aggressive malignant astrocytic tumors,
contain a small subpopulation of cancer stem cells (GSCs) that are implicated in therapeutic …

Therapeutic benefit in glial tumors is often limited due to low permeability of delivery systems
across the blood− brain barrier (BBB), drug resistance, and poor penetration into the tumor …

Liver cancer stem cells (LCSCs) can drive and maintain hepatocellular carcinoma (HCC)
growth, metastasis, and recurrence. Therefore, they are potentially responsible for the poor …

We have constructed a drug delivery vehicle that targets the epidermal growth factor
receptor (EGFR) and its mutant isoform EGFRvIII. The monoclonal antibody, cetuximab …

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. GBM contains
a small subpopulation of glioma stem cells (GSCs) that are implicated in treatment …